Payment overview · 2025
General Payments
$850.55
51 reported records · 11 companies
Healthcare provider profile · identity verified
David J Etzel, CNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · SHELBY, OH · NPI 1881999555
Verified facts
What the public records show
CMS Open Payments records show David J Etzel, CNP received $850.55 in general payments during 2025 across 51 reported records.
ABBVIE INC. accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $289.74 | 34.1% | 19 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $156.28 | 18.4% | 10 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $152.50 | 17.9% | 8 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.88 | 5.6% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $40.59 | 4.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.29 | 3.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.22 | 3.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $32.54 | 3.8% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $29.57 | 3.5% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $18.24 | 2.1% | 1 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $16.70 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $850.55 | 51 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $184.03 | 11 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $156.28 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $117.72 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $105.71 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $75.56 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $68.09 | 5 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $47.88 | 3 | 2025 |
Source payment records
|
|||||
| VIVITROL Normalized: vivitrol |
Drug | Alkermes, Inc. | $40.59 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $32.54 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $29.57 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $18.24 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.24 | 1 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $16.70 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.98 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
56 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 323 | 73 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 252 | 67 |
| Gabapentin | Gabapentin | 234 | 42 |
| Omeprazole | Omeprazole | 219 | 44 |
| Levothyroxine Sodium | Levothyroxine Sodium | 210 | 45 |
| Lisinopril | Lisinopril | 207 | 50 |
| Furosemide | Furosemide | 139 | 32 |
| Metformin Hcl | Metformin Hcl | 136 | 38 |
| Amlodipine Besylate | Amlodipine Besylate | 124 | 33 |
| Losartan Potassium | Losartan Potassium | 121 | 33 |
| Potassium Chloride | Potassium Chloride | 120 | 26 |
| Montelukast Sodium | Montelukast Sodium | 116 | 29 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 25 |
| Prednisone | Prednisone | 106 | 63 |
| Simvastatin | Simvastatin | 102 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 95 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 87 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 82 | 24 |
| Buspirone Hcl | Buspirone Hcl | 79 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 78 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 75 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 70 | 20 |
| Sertraline Hcl | Sertraline Hcl | 70 | 15 |
| Pioglitazone Hcl | Pioglitazone Hcl | 69 | 12 |
| Famotidine | Famotidine | 68 | 15 |
| Glipizide | Glipizide | 67 | 18 |
| Trazodone Hcl | Trazodone Hcl | 63 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 62 | 19 |
| Farxiga | Dapagliflozin Propanediol | 61 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 60 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 59 | 11 |
| Allopurinol | Allopurinol | 58 | 18 |
| Clonidine Hcl | Clonidine Hcl | 57 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 14 |
| Eliquis | Apixaban | 56 | 11 |
| Carvedilol | Carvedilol | 55 | 14 |
| Azithromycin | Azithromycin | 53 | 40 |
| Meloxicam | Meloxicam | 52 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 18 |
| Baclofen | Baclofen | 47 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 44 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 39 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 39 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Pregabalin | Pregabalin | 37 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 34 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 34 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Trulicity | Dulaglutide | 34 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 31 | 13 |
| Ibuprofen | Ibuprofen | 31 | 15 |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 31 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Glimepiride | Glimepiride | 30 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 24 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 24 | suppressed |
| Mirtazapine | Mirtazapine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Fluconazole | Fluconazole | 23 | 14 |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Nabumetone | Nabumetone | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Levemir Flexpen | Insulin Detemir | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | 12 |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Invokana | Canagliflozin | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Jardiance | Empagliflozin | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 15 | suppressed |
| Indomethacin | Indomethacin | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Sulindac | Sulindac | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Digoxin | Digoxin | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Gemfibrozil | Gemfibrozil | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 12 | suppressed |
| Alprazolam | Alprazolam | 11 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $850.55 · 51 records | ABBVIE INC. | AIRSUPRA, BREZTRI, BRIXADI, CAPLYTA, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, GVOKE HYPOPEN, NURTEC ODT, Ozempic, PAXLOVID, QULIPTA, Rybelsus, SUBLOCADE, UBRELVY, VIVITROL, VRAYLAR, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error